|
Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Technical Data
| Formula | C11H11NO3 |
|||
| Molecular Weight | 205.21 | CAS No. | 6501-72-0 | |
| Solubility (25°C)* | In vitro | DMSO | 41 mg/mL (199.79 mM) | |
| Ethanol | 41 mg/mL (199.79 mM) | |||
| Water | Insoluble | |||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
||||
Preparing Stock Solutions
Biological Activity
| Description | VGX-1027 (GIT 27) is an orally active immunomodulator. Phase 1. |
|---|---|
| In vitro | VGX-1027 significantly inhibits both IL-1β/IFN-γ-induced TNF-α and nitrite accumulation, and causes a significant increase in cell survival by interfering with the cytotoxic effects of the cytokines. [1] VGX-1027 inhibits both proliferation of enterobacterial antigen-reactive CD4+CD25− T cells in vitro. [2] |
| In vivo | VGX-1027 prevents development of spontaneous type 1 diabetes in NOD Mice and counteracts accelerated diabetogenesis induced by cyclophosphamide challenge or adoptive transfer of diabetogenic spleen cells in NOD Mice. VGX-1027 also reduces clinical signs of MLD-STZ-induced diabetes and suppresses pathohistological changes of pancreas. [1] VGX-1027 suppresses the development of clinical, histological and immunological signs of DNBS-induced colitis in CD1 mice. [2] In NZB/NZW F1 model of systemic lupus erythematosus (SLE), VGX-1027 ameliorates the course of the disease with higher percent survival and improved clinical and histopathological signs. [3] |
Protocol (from reference)
| Animal Study:[1] |
|
|---|
References
|
Selleck's VGX-1027 has been cited by 1 publication
| Protective effects of VGX-1027 in PM2.5-induced airway inflammation and bronchial hyperresponsiveness. [ Eur J Pharmacol, 2019, 842:373-383] | PubMed: 30419239 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.